Nuvalent reported promising efficacy data for zidesamtinib, its ROS1-targeted therapy for non-small cell lung cancer patients who have failed existing treatments. The drug achieved a 44% objective response rate in a pivotal mid-stage study and is poised to initiate a rolling New Drug Application with the FDA. Nuvalent aims to address the unmet clinical need in this niche indication with potentially improved efficacy and tolerability, positioning the drug competitively in the growing targeted therapy market.